499 related articles for article (PubMed ID: 20091460)
1. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
[TBL] [Abstract][Full Text] [Related]
2. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.
Laudes M; Oberhauser F; Schulte DM; Schilbach K; Freude S; Bilkovski R; Schulz O; Faust M; Krone W
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):473-7. PubMed ID: 20198559
[TBL] [Abstract][Full Text] [Related]
4. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression.
Moschen AR; Molnar C; Wolf AM; Weiss H; Graziadei I; Kaser S; Ebenbichler CF; Stadlmann S; Moser PL; Tilg H
J Hepatol; 2009 Oct; 51(4):765-77. PubMed ID: 19664840
[TBL] [Abstract][Full Text] [Related]
5. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease.
Moschen AR; Geiger S; Gerner R; Tilg H
Mutat Res; 2010 Aug; 690(1-2):95-101. PubMed ID: 19583971
[TBL] [Abstract][Full Text] [Related]
6. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Mercader J; Granados N; Caimari A; Oliver P; Bonet ML; Palou A
Horm Metab Res; 2008 Jul; 40(7):467-72. PubMed ID: 18401839
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
[TBL] [Abstract][Full Text] [Related]
8. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine.
Sommer G; Garten A; Petzold S; Beck-Sickinger AG; Blüher M; Stumvoll M; Fasshauer M
Clin Sci (Lond); 2008 Jul; 115(1):13-23. PubMed ID: 19016657
[TBL] [Abstract][Full Text] [Related]
9. Nampt and its potential role in inflammation and type 2 diabetes.
Garten A; Petzold S; Schuster S; Körner A; Kratzsch J; Kiess W
Handb Exp Pharmacol; 2011; (203):147-64. PubMed ID: 21484571
[TBL] [Abstract][Full Text] [Related]
10. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.
Retnakaran R; Youn BS; Liu Y; Hanley AJ; Lee NS; Park JW; Song ES; Vu V; Kim W; Tungtrongchitr R; Havel PJ; Swarbrick MM; Shaw C; Sweeney G
Clin Endocrinol (Oxf); 2008 Dec; 69(6):885-93. PubMed ID: 18410550
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats.
Sun Q; Li L; Li R; Yang M; Liu H; Nowicki MJ; Zong H; Xu J; Yang G
Ann Med; 2009; 41(4):311-20. PubMed ID: 19263259
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women.
Unlütürk U; Harmanci A; Yildiz BO; Bayraktar M
Clin Endocrinol (Oxf); 2010 Apr; 72(4):469-74. PubMed ID: 19650786
[TBL] [Abstract][Full Text] [Related]
13. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle.
de Luis DA; Sagrado MG; Aller R; Conde R; Izaola O
Nutrition; 2010; 26(11-12):1130-3. PubMed ID: 19211226
[TBL] [Abstract][Full Text] [Related]
14. Serum resistin levels in Syrian obese patients with diabetes mellitus type II.
Al-Sari IE; Al-Quobaili FA; Kabalan YM
Saudi Med J; 2007 Dec; 28(12):1890-4. PubMed ID: 18060223
[TBL] [Abstract][Full Text] [Related]
15. Visfatin expression is elevated in normal human pregnancy.
Morgan SA; Bringolf JB; Seidel ER
Peptides; 2008 Aug; 29(8):1382-9. PubMed ID: 18524416
[TBL] [Abstract][Full Text] [Related]
16. Visfatin, low-grade inflammation and body mass index (BMI).
Samara A; Pfister M; Marie B; Visvikis-Siest S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):568-74. PubMed ID: 18248642
[TBL] [Abstract][Full Text] [Related]
17. Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases.
Motawi TM; Shaker OG; El-Sawalhi MM; Abdel-Nasser ZM
Genome; 2014 May; 57(5):259-66. PubMed ID: 25120107
[TBL] [Abstract][Full Text] [Related]
18. Serum visfatin, resistin and IL-18 in A group of Egyptian obese diabetic and non diabetic individuals.
Mabrouk R; Ghareeb H; Shehab A; Omar K; El-Kabarity RH; Soliman DA; Mohamed NA
Egypt J Immunol; 2013; 20(1):1-11. PubMed ID: 23888552
[TBL] [Abstract][Full Text] [Related]
19. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes.
Garten A; Petzold S; Barnikol-Oettler A; Körner A; Thasler WE; Kratzsch J; Kiess W; Gebhardt R
Biochem Biophys Res Commun; 2010 Jan; 391(1):376-81. PubMed ID: 19912992
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
